Evidence map›Paper›PMID 41634106›Full record

ArticleScientific reports2026

Machine learning framework for mRNA alternative splicing analysis identifies a signature of progression in colorectal adenocarcinoma.

Uran Maimekov, Mehdi Nosrati, Ahmed Mahmoud, Mainak Mustafi, Michael W Craige, Frederick Coffman, J Scott Parrott, Carol Lutz, Antonina Mitrofanova

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Uran MaimekovRutgers Biomedical and Health Sciences, Rutgers School of Graduate Studies, Newark, NJ, 07039, USA.
Mehdi NosratiDepartment of Health Informatics, Rutgers School of Health Professions, Newark, NJ, 07107, USA.
Ahmed MahmoudDepartment of Health Informatics, Rutgers School of Health Professions, Newark, NJ, 07107, USA.
Mainak MustafiDepartment of Health Informatics, Rutgers School of Health Professions, Newark, NJ, 07107, USA.
Michael W CraigeDepartment of Health Informatics, Rutgers School of Health Professions, Newark, NJ, 07107, USA.
Frederick CoffmanDepartment of Health Informatics, Rutgers School of Health Professions, Newark, NJ, 07107, USA.
J Scott ParrottDepartment of Interdisciplinary Studies, Rutgers School of Health Professions, Newark, NJ, 07107, USA.
Carol LutzDepartment of Microbiology, Biochemistry & Molecular Genetics, Rutgers Biomedical & Health Sciences, New Jersey Medical School, Newark, NJ, 07103, USA.
Antonina MitrofanovaDepartment of Health Informatics, Rutgers School of Health Professions, Newark, NJ, 07107, USA. amitrofa@shp.rutgers.edu.

Funding

American Cancer Society RSG-21-023-01-TBGComputing Research Association 2127309Congressionally Directed Medical Research Programs HT94252410346U.S. National Library of Medicine R01LM013236
6 · The paper itself

Abstract

Despite recent advances in genome-wide profiling and the discovery of novel therapeutic options for colorectal adenocarcinoma (COAD), effective patient classification for the risk of cancer progression remains underdeveloped. Recent research has highlighted the crucial role of mRNA alternative splicing (AS) in the development and progression of COAD, yet a genome-wide comprehensive evaluation of the role of AS in COAD progression has not been implemented. In this study, we present a robust machine-learning framework designed to uncover clinically relevant AS events associated with progression-free survival (PFS) in COAD patients. For this, we analyzed RNA sequencing data from the TCGA-COAD cohort (n = 266). We employed a machine learning approach integrating Cox Proportional Hazards (PH) analysis and Robust Likelihood-Based Survival (RBSURV) modeling that identified a five-event AS-PFS signature (spanning AS events in OR52K1, SPIN3, NDUFV1, BMPR1A, and ARPC4 genes). By leveraging this signature, we defined a risk score for each patient, categorizing them into low and high-risk groups. This signature and its risk score were further validated through Kaplan-Meier survival analysis and time-dependent receiver operating characteristic (ROC) analysis in the TCGA-COAD test set and independent patient cohort AC-ICAM (n = 348). Comparison to other markers and methods further confirmed the independent predictive value of the AS-PFS risk signature. We propose that this signature could be utilized in clinical settings to enhance patient stratification at diagnosis and further inform personalized treatment strategies.

Indexed as

AdenocarcinomaAlternative SplicingColorectal NeoplasmsMachine LearningRNA, MessengerDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleProgression-Free SurvivalRNA, Messenger

Identifiers

PMID41634106
PMCPMC12920883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.